Heron Therapeutics, Inc. (HRTX) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 12, 2025. Heron Therapeutics, Inc., a Delaware corporation, is listed on The Nasdaq Capital Market under the symbol HRTX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the Record Date (April 15, 2025), 152,530,696 shares were outstanding. At the meeting, 120,003,504 shares were represented, constituting a quorum. Stockholders voted on four proposals:
- Proposal 1 (Election of Directors): All six nominees were elected. Significant broker non-votes (35,904,582 shares) were recorded for each nominee.
- Craig Collard: 82,777,195 For
- Sharmila Dissanaike: 81,364,822 For
- Craig Johnson: 81,742,495 For
- Michael Kaseta: 81,849,779 For
- Adam Morgan: 82,815,802 For
- Christian Waage: 79,359,803 For
- Proposal 2 (Ratification of Auditors): Withum Smith+Brown, PC was ratified with 118,578,049 votes For and 1,033,191 votes Against.
- Proposal 3 (Say-on-Pay): Executive compensation for the fiscal year ended December 31, 2024, was approved with 79,260,872 votes For and 3,528,575 votes Against.
- Proposal 4 (Say-on-Pay Frequency): Stockholders approved an annual frequency for future advisory votes on executive compensation with 80,506,750 votes for 1 Year.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, risks, contingencies, or unusual items. The Company intends to hold annual advisory votes on executive compensation consistent with the stockholder recommendation.
Investor Verification Checklist
- Verify the specific terms of employment and compensation for the newly elected directors and Named Executive Officers.
- Review the full proxy statement for details on the "Against" votes and abstentions, particularly for Director Christian Waage who received the highest number of "Against" votes (4,687,202).
- Confirm the Company's cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor the Company's pipeline updates, as the filing does not address clinical trial progress or regulatory milestones.